Sebastian Gensior

ARCH Venture Partners has raised over $3 billion for its thirteenth fund, cementing its position as one of biotech's most influential venture capital firms. The Chicago-based firm, which originated from a University of Chicago technology transfer initiative in 1986, has evolved into an investment powerhouse managing approximately

The recent closure of AlpInvest's $1 billion collateralized fund obligation marks a potential inflection point for biotech financing. This complex financial structure, dormant since the 2008 financial crisis, could unlock trillions in insurance capital for an industry perpetually hungry for funding. But as private equity rushes into pharmaceutical

Where natural selection meets unnatural hotel ballroom lighting In the grand ecosystem of biotechnology conferences, where PowerPoint presentations battle for attention spans and coffee quality determines afternoon session attendance, choosing the right events has become as complex as selecting lead compounds for clinical development. The modern biotech executive faces a

EU AI Act: Pharmaceutical AI Compliance Framework EU AI Act Classification High-Risk AI Systems Pharmaceutical AI Applications Documentation Requirements Risk Assessment Protocols Human Oversight Mandates Infrastructure Implications On-Premises Advantages Cloud Compliance Challenges Legend: Regulatory Framework Compliance Requirements Preferred Solution Standard Process Source: EU AI Act (2024), EMA AI

Private equity firms deployed $5.42 billion into biotech and pharmaceutical royalty transactions through 2025, marking a 7% increase from the previous year despite broader market turbulence. The acquisition of HealthCare Royalty Partners by KKR in July 2025, adding $3 billion in assets under management to the private equity giant&

Pharma & biotech deals heat up with $5B+ in transactions The week of August 11-15, 2025 witnessed a striking bifurcation in pharmaceutical and biotech dealmaking: while venture capital remained frozen in an unprecedented funding drought, strategic partnerships and public markets surged with over $5 billion in total transaction value.

These are the voyages of a new class of pharmaceutical pioneers. Their five-year mission: to explore strange crystallization conditions, to seek out novel polymorphs and new delivery systems, to boldly compound where no molecule has compounded before. In the past two years, the once-theoretical concept of orbiting drug

Finding the spice in RNA's vast landscape Arrakis Therapeutics has positioned itself as a pioneer in RNA-targeted small molecules, securing $378 million in total funding including $265 million in upfront partnership payments from pharmaceutical giants Roche and Amgen as of August 2025. The Waltham-based company, named

RTW Investments has transformed from a specialized healthcare hedge fund into a $9.8 billion life sciences investment platform that bridges the gap between academic discovery and commercial success. Founded in 2009 by Dr. Roderick Wong, the firm operates at the intersection of deep scientific expertise and sophisticated financial engineering,

Risk-Adjusted NPV (rNPV) in Biotech Valuation The rNPV Formula rNPV = Σ [P(success) × NPV(success) + P(fail) × NPV(fail)] Explicitly models binary outcomes in drug development ✅ Success Scenario (50% probability) Drug approved, market entry NPV = $2.0B ❌ Failure Scenario (50% probability) Trial fails, no approval NPV = $0 🎯 Risk-Adjusted